Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

Investigation.blog.lemonde.fr

http://www.clinicaltrials.gov/ct/show/NCT00088699 Rapid Antidepressant Effects of Ketamine
This study is currently recruiting patients.

Verified by National Institutes of Health Clinical Center (CC) May 2006 Sponsored by:
National Institutes of Health Clinical Center Information provided by: (CC)
ClinicalTrials.gov Identifier: NCT00088699
This study will test whether a single dose of ketamine - a drug that blocks a brain receptor called NMDA - can cause a rapid (next day) antidepressant effect in patients with major depression. Several medications are effective for treating depression; however, they take weeks or months to achieve their full effects. A more rapidly acting antidepressant would have a significant impact on the treatment of depression. In a previous study, ketamine produced a rapid antidepressant effect within hours, but the effect lasted less than 1 week. Understanding how ketamine works may lead to a better understanding of the causes of depression and the design of a longer lasting rapidly acting antidepressant. Patients between 18 and 65 years of age who are currently experiencing an episode of major depression of at least 4 weeks duration and have not responded to two treatment trials may be eligible for this study. Candidates are screened with a medical and psychiatric history, physical examination, and blood and urine tests. Participants undergo the following tests and procedures:  Medication tapering: Patients who are taking medications for depression are tapered off the  Ketamine/placebo trial: Patients are given a single dose of either ketamine or placebo (an inactive substance), administered intravenously (through a vein) over 40 minutes. After 7 days, patients are given another dose of study drug in crossover fashion; that is, those who previously took ketamine are switched to receive placebo, and those who took placebo are switched to ketamine. Oximetry (measurement of blood oxygen), pulse, and blood pressure are measured continuously for 1 hour before and 4 hours after each ketamine or placebo dose to monitor safety.  Interviews and rating scales: Patients complete a series of psychiatric rating scales to assess the effects of the study drug on mood and thinking. The rating scales are repeated up to 18 times during the study, with each time taking about 15 to 20 minutes.  Physical examination and laboratory tests: Patients have a physical examination, blood tests, weight measure, and electrocardiogram (ECG) at the beginning and end of the study. Atendemos pacientes de habla hispana.
Condition
Intervention
related topics: Study Type: InterventionalStudy Design: Treatment Official Title: Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA AntagonistFurther study details as provided by National Institutes of Health Clinical Center (CC):Primary Outcomes: Reduction from baseline of the HDRS between groups.
Expected Total Enrollment: 101 Study start: July 2004Last follow-up: May 2006; Data entry closure: May 2006 Bipolar affective disorder (manic-depressive illness) and unipolar depression are common, severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses. Recent preclinical and clinical studies suggest that the glutamatergic system is involved in the mechanism of action of antidepressants. In two separate trials, we tested riluzole (an inhibitor of glutamate release) and found it to have antidepressant properties in patients with unipolar and bipolar depression (Zarate et al. 2004, 2005). In another study, we found that the non-competitive NMDA antagonist (ketamine) was effective in treatment-resistant major depression. Ketamine resulted in rapid, robust and relatively sustained antidepressant effects. Response with ketamine occurred within 2 hours and last approximately 1 week (Zarate et al in press). The current protocol consists of 3 studies designed to address 3 major questions: Study 1 (Rapid improvement research in unipolar depression):Does the NMDA antagonist ketamine produce rapid antidepressant effects in patients with treatment-resistant major depression? Patients, ages 18 to 65 years with treatment-resistant major (unipolar) depression will in a double-blind crossover study receive either intravenous ketamine or saline solution. Study 2 (Rapid improvement research in bipolar depression):Does the NMDA antagonist ketamine produce rapid antidepressant effects in patients with treatment-resistant bipolar depression? Patients, ages 18 to 65 years with treatment-resistant bipolar depression will in a double-blind crossover study receive either intravenous ketamine or saline solution added to a mood stabilizer (lithium or valproate). Study 3 (Rapid and sustained improvement research in unipolar depression):Does riluzole (an inhibitor of glutamate release) prevent relapse in patients with treatment-resistant major depression who have rapidly responded to a single intravenous dose of ketamine? Patients, ages 18 to 65 years, with treatment-resistant major (unipolar) depression who have rapidly responded to a single intravenous dose of ketamine will in a double-blind study receive either riluzole or placebo to determine if the rapid response obtained can be sustained. Our primary hypotheses for these studies are: 1) rapid response (same or next day) can be achieved in patients with treatment-resistant major (unipolar) depression, 2) rapid response (same or next day) can be achieved in patients with treatment-resistant bipolar depression, and 3) rapid response (same or next day) can be sustained in patients with treatment-resistant unipolar depression. Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both Criteria • Male or female subjects, 18 to 65 years of age. • Female subjects of childbearing potential must be using a medically accepted means • Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. • Subjects must fulfill DSM-IV criteria for Major Depression (296.3) without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview, SCID-P. • Subjects must have an initial score of at least 22 on the MADRS at screen and at • Subjects with a greater than a 25% decrease in the MADRS total scores between screen and baseline of study phase I will be dropped from the study. • Current or past history of lack of response to two adequate antidepressant trials (may be from the same chemical class) operationally defined using the Antidepressant Treatment History Form (ATHF). • Current major depressive episode of at least 4 weeks duration.
• Presence of psychotic features or a diagnosis of Schizophrenia or any other psychotic • Subjects with a history of DSM-IV drug or alcohol dependency or abuse (excluding nicotine or caffeine) within the preceding 3 months. • Female subjects who are either pregnant or nursing. • Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. • Subjects with uncorrected hypothyroidism or hyperthyroidism. • Subjects with one or more seizures without a clear and resolved etiology. • Previous treatment with riluzole or hypersensitivity to it or to amantadine. • Previous lack of response to ketamine for depression. • Treatment with a reversible MAOI within 2 weeks prior to study phase I. • Treatment with fluoxetine within 5 weeks prior to study phase I. • Treatment with any other concomitant medication not allowed 14 days prior to study • No structured psychotherapy will be permitted during the study. 1. Response to a single dose of ketamine (less than or equal to 12 MADRS from baseline). 2. YMRS less than or equal to 15. Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00088699 PRPL Maryland
National Institute of Mental Health (NIMH), Bethesda, Maryland, 20892, United
States; Recruiting
More Information
Study ID Numbers: 040222; 04-M-0222Last Updated: June 19, 2006Record first received: June 19, 2006ClinicalTrials.gov Identifier: Health Authority: United States: Federal GovernmentClinicalTrials.gov processed this record on 2006-07-25

Source: http://investigation.blog.lemonde.fr/files/2007/01/test-ketamine.pdf

Microsoft word - new patient questionnaire

Name________________________________ Nickname (If preferred)__________________ Date of Birth___/____/____ Age______ Female / Male Current weight_______ one year ago______ Maximum weight________ Height_________ Drug allergies_______________________________________________________________________________________ Reasons for this visit- please include your most important health concerns in order

legacyfurniture.us

Care WOrK SHeeT ONE (1) COLLECTION PER WORK SHEET Customer Name: ________________________________________________ P.O. #: ______________________________________________________________ STEP 1-Circle ONE Desired Collection Name. Then Enter Quantities of Each Item (One Collection Only-Additional collections require separate work sheets.) Enter Qty Circle Collection Transformer Tr

Copyright © 2010-2014 Medicament Inoculation Pdf